Skip to main content
Top
Published in: Breast Cancer Research 4/2007

Open Access 01-08-2007 | Research article

Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients

Authors: Javier Silva, Vanesa García, José M García, Cristina Peña, Gemma Domínguez, Raquel Díaz, Yolanda Lorenzo, Alicia Hurtado, Antonio Sánchez, Félix Bonilla

Published in: Breast Cancer Research | Issue 4/2007

Login to get access

Abstract

Introduction

Deregulation of Polycomb member Bmi-1 is involved in cell proliferation and human oncogenesis. Modulation of Bmi-1 is found in several tumor tissues, including primary breast carcinomas; however, analysis of Bmi-1 in plasma of cancer patients has not been reported. This is the first study that evaluates Bmi-1 in plasma by using a large series of primary breast carcinomas to investigate the presence at diagnosis of detectable Bmi-1 mRNA in plasma and possible correlations between this event and a series of clinical-pathological parameters of the tumors.

Methods

Bmi-1 expression levels were quantified in plasma of 111 breast cancer patients and in 20 healthy controls by real-time quantitative polymerase chain reaction.

Results

Cancer patients with the presence of Bmi-1 mRNA in plasma had higher levels of Bmi-1 expression than healthy controls with Bmi-1 mRNA in plasma. The higher expression levels of Bmi-1 correlated with well-established markers of poor clinical outcome in breast cancer such as positive p53 immunostaining and negative progesterone receptors. Moreover, we described for the first time a statistically significant correlation between Bmi-1 expression in plasma of breast cancer patients and disease-free and overall survival in advanced stages.

Conclusion

Our results suggest that levels of Bmi-1 expression may be a surrogate marker of poor prognosis and may become clinically useful as noninvasive diagnostic markers.
Appendix
Available only for authorised users
Literature
1.
go back to reference Leon SA, Shapiro B, Sklaroff DM, Yaros MJ: Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977, 37: 646-650.PubMed Leon SA, Shapiro B, Sklaroff DM, Yaros MJ: Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977, 37: 646-650.PubMed
2.
go back to reference Shapiro B, Chakrabarty M, Cohn EM, Leon SA: Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer. 1983, 51: 2116-2120. 10.1002/1097-0142(19830601)51:11<2116::AID-CNCR2820511127>3.0.CO;2-S.CrossRefPubMed Shapiro B, Chakrabarty M, Cohn EM, Leon SA: Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease. Cancer. 1983, 51: 2116-2120. 10.1002/1097-0142(19830601)51:11<2116::AID-CNCR2820511127>3.0.CO;2-S.CrossRefPubMed
3.
go back to reference Anker P, Lefort F, Vasioukhin V, Lyautey J, Lederrey C, Chen XQ, Stroun M, Mulcahy HE, Farthing MJ: K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. Gastroenterology. 1997, 112: 1114-1120. 10.1016/S0016-5085(97)70121-5.CrossRefPubMed Anker P, Lefort F, Vasioukhin V, Lyautey J, Lederrey C, Chen XQ, Stroun M, Mulcahy HE, Farthing MJ: K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. Gastroenterology. 1997, 112: 1114-1120. 10.1016/S0016-5085(97)70121-5.CrossRefPubMed
4.
go back to reference Silva JM, Gonzalez R, Dominguez G, Garcia JM, España P, Bonilla F: TP53 gene mutations in plasma DNA of cancer patients. Genes Chromosomes Cancer. 1999, 24: 160-161. 10.1002/(SICI)1098-2264(199902)24:2<160::AID-GCC10>3.0.CO;2-C.CrossRefPubMed Silva JM, Gonzalez R, Dominguez G, Garcia JM, España P, Bonilla F: TP53 gene mutations in plasma DNA of cancer patients. Genes Chromosomes Cancer. 1999, 24: 160-161. 10.1002/(SICI)1098-2264(199902)24:2<160::AID-GCC10>3.0.CO;2-C.CrossRefPubMed
5.
go back to reference Chen XQ, Stroun M, Magnenat JL, Nicod LP, Kurt AM, Lyautey J, Lederrey C, Anker P: Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med. 1996, 2: 1033-1035. 10.1038/nm0996-1033.CrossRefPubMed Chen XQ, Stroun M, Magnenat JL, Nicod LP, Kurt AM, Lyautey J, Lederrey C, Anker P: Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med. 1996, 2: 1033-1035. 10.1038/nm0996-1033.CrossRefPubMed
6.
go back to reference Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, Lee JC, Hjelm NM, Johnson PJ, Huang DP: Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 1999, 59: 1188-1191.PubMed Lo YM, Chan LY, Lo KW, Leung SF, Zhang J, Chan AT, Lee JC, Hjelm NM, Johnson PJ, Huang DP: Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. Cancer Res. 1999, 59: 1188-1191.PubMed
7.
go back to reference Silva JM, Dominguez G, Garcia JM, Gonzalez R, Villanueva MJ, Navarro F, Provencio M, San Martin S, España P, Bonilla F: Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. Cancer Res. 1999, 59: 3251-3256.PubMed Silva JM, Dominguez G, Garcia JM, Gonzalez R, Villanueva MJ, Navarro F, Provencio M, San Martin S, España P, Bonilla F: Presence of tumor DNA in plasma of breast cancer patients: clinicopathological correlations. Cancer Res. 1999, 59: 3251-3256.PubMed
8.
go back to reference Silva JM, Silva J, Sanchez A, Garcia JM, Dominguez G, Provencio M, Sanfrutos L, Jareño E, Colas A, España P, et al: Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor for disease-free survival. Clin Cancer Res. 2002, 8: 3761-3766.PubMed Silva JM, Silva J, Sanchez A, Garcia JM, Dominguez G, Provencio M, Sanfrutos L, Jareño E, Colas A, España P, et al: Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor for disease-free survival. Clin Cancer Res. 2002, 8: 3761-3766.PubMed
9.
go back to reference Taback B, Fujiwara Y, Wang HJ, Foshag LJ, Morton DL, Hoon DS: Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients. Cancer Res. 2001, 61: 5723-5726.PubMed Taback B, Fujiwara Y, Wang HJ, Foshag LJ, Morton DL, Hoon DS: Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients. Cancer Res. 2001, 61: 5723-5726.PubMed
10.
go back to reference Shao ZM, Wu J, Shen ZZ, Nguyen M: p53 mutations in plasma DNA and its prognostic value in breast cancer patients. Clin Cancer Res. 2001, 7: 2222-2227.PubMed Shao ZM, Wu J, Shen ZZ, Nguyen M: p53 mutations in plasma DNA and its prognostic value in breast cancer patients. Clin Cancer Res. 2001, 7: 2222-2227.PubMed
11.
go back to reference Kopreski MS, Benko FA, Kwak LW, Gocke CD: Detection of tumor messenger RNA in serum of patients with malignant melanoma. Clin Cancer Res. 1999, 5: 1961-1965.PubMed Kopreski MS, Benko FA, Kwak LW, Gocke CD: Detection of tumor messenger RNA in serum of patients with malignant melanoma. Clin Cancer Res. 1999, 5: 1961-1965.PubMed
12.
go back to reference Chen XQ, Bonnefoi H, Pelte MF, Lyautey J, Lederrey C, Movarekhi S, Schaeffer P, Mulcahy HE, Meyer P, Stroun M, et al: Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res. 2000, 6: 3823-3826.PubMed Chen XQ, Bonnefoi H, Pelte MF, Lyautey J, Lederrey C, Movarekhi S, Schaeffer P, Mulcahy HE, Meyer P, Stroun M, et al: Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res. 2000, 6: 3823-3826.PubMed
13.
go back to reference Silva JM, Dominguez G, Silva J, Garcia JM, Sanchez A, Rodriguez O, Provencio M, España P, Bonilla F: Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics. Clin Cancer Res. 2001, 7: 2821-2825.PubMed Silva JM, Dominguez G, Silva J, Garcia JM, Sanchez A, Rodriguez O, Provencio M, España P, Bonilla F: Detection of epithelial messenger RNA in the plasma of breast cancer patients is associated with poor prognosis tumor characteristics. Clin Cancer Res. 2001, 7: 2821-2825.PubMed
14.
go back to reference Dasí F, Lledó S, García-Granero E, Ripoll R, Marugán M, Tormo M, García-Conde J, Aliño SF: Real-time quantification in plasma of human telomerase reverse transcriptase [hTERT] mRNA: a simple blood test to monitor disease in cancer patients. Lab Invest. 2001, 81: 767-769.CrossRefPubMed Dasí F, Lledó S, García-Granero E, Ripoll R, Marugán M, Tormo M, García-Conde J, Aliño SF: Real-time quantification in plasma of human telomerase reverse transcriptase [hTERT] mRNA: a simple blood test to monitor disease in cancer patients. Lab Invest. 2001, 81: 767-769.CrossRefPubMed
15.
go back to reference Silva JM, Rodriguez R, Garcia JM, Muñoz C, Silva J, Dominguez G, Provencio M, España P, Bonilla F: Detection of epithelial tumor RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. Gut. 2002, 50: 530-534. 10.1136/gut.50.4.530.CrossRefPubMedPubMedCentral Silva JM, Rodriguez R, Garcia JM, Muñoz C, Silva J, Dominguez G, Provencio M, España P, Bonilla F: Detection of epithelial tumor RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. Gut. 2002, 50: 530-534. 10.1136/gut.50.4.530.CrossRefPubMedPubMedCentral
16.
go back to reference Wong SC, Lo SF, Cheung MT, Ng KO, Tse CW, Lai BS, Lee KC, Lo YM: Quantification of plasma beta-catenin mRNA in colorectal cancer and adenoma patients. Clin Cancer Res. 2004, 10: 1613-1617. 10.1158/1078-0432.CCR-1168-3.CrossRefPubMed Wong SC, Lo SF, Cheung MT, Ng KO, Tse CW, Lai BS, Lee KC, Lo YM: Quantification of plasma beta-catenin mRNA in colorectal cancer and adenoma patients. Clin Cancer Res. 2004, 10: 1613-1617. 10.1158/1078-0432.CCR-1168-3.CrossRefPubMed
17.
go back to reference Lo KW, Lo YM, Leung SF, Tsang YS, Chan LY, Johnson PJ, Hjelm NM, Lee JC, Huang DP: Analysis of cell-free Epstein-Barr virus-associated RNA in the plasma of patients with nasopharyngeal carcinoma. Clin Chem. 1999, 45: 1292-1294.PubMed Lo KW, Lo YM, Leung SF, Tsang YS, Chan LY, Johnson PJ, Hjelm NM, Lee JC, Huang DP: Analysis of cell-free Epstein-Barr virus-associated RNA in the plasma of patients with nasopharyngeal carcinoma. Clin Chem. 1999, 45: 1292-1294.PubMed
18.
go back to reference Silva J, Silva JM, García V, García JM, Domínguez G, Bonilla F: RNA is more sensitive than DNA in identification of breast cancer patients bearing tumor nucleic acids in plasma. Genes Chromosomes Cancer. 2002, 35: 375-376. 10.1002/gcc.10124.CrossRefPubMed Silva J, Silva JM, García V, García JM, Domínguez G, Bonilla F: RNA is more sensitive than DNA in identification of breast cancer patients bearing tumor nucleic acids in plasma. Genes Chromosomes Cancer. 2002, 35: 375-376. 10.1002/gcc.10124.CrossRefPubMed
19.
go back to reference Francis NJ, Kingston RE: Mechanisms of transcriptional memory. Nat Rev Mol Cell Biol. 2001, 2: 409-421. 10.1038/35073039.CrossRefPubMed Francis NJ, Kingston RE: Mechanisms of transcriptional memory. Nat Rev Mol Cell Biol. 2001, 2: 409-421. 10.1038/35073039.CrossRefPubMed
20.
go back to reference Raaphorst FM: Deregulated expression of polycomb-group oncogenes in human malignant lymphomas and epithelial tumours. Hum Mol Genet. 2005, 14: 93-100. 10.1093/hmg/ddi111.CrossRef Raaphorst FM: Deregulated expression of polycomb-group oncogenes in human malignant lymphomas and epithelial tumours. Hum Mol Genet. 2005, 14: 93-100. 10.1093/hmg/ddi111.CrossRef
21.
go back to reference Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M: Stem cells and cancer; the polycomb connection. Cell. 2004, 118: 409-418. 10.1016/j.cell.2004.08.005.CrossRefPubMed Valk-Lingbeek ME, Bruggeman SW, van Lohuizen M: Stem cells and cancer; the polycomb connection. Cell. 2004, 118: 409-418. 10.1016/j.cell.2004.08.005.CrossRefPubMed
22.
go back to reference Gil J, Bernard D, Peters G: Role of Polycomb group proteins in stem cell-renewal and cancer. DNA Cell Biol. 2005, 24: 117-125. 10.1089/dna.2005.24.117.CrossRefPubMed Gil J, Bernard D, Peters G: Role of Polycomb group proteins in stem cell-renewal and cancer. DNA Cell Biol. 2005, 24: 117-125. 10.1089/dna.2005.24.117.CrossRefPubMed
23.
go back to reference Jacobs JJ, Scheijen B, Voncken JW, Kieboom K, Berns A, van Lohuizen M: Bmi-1 collaborates with c-Myc in tumourigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev. 1999, 13: 2678-2690. 10.1101/gad.13.20.2678.CrossRefPubMedPubMedCentral Jacobs JJ, Scheijen B, Voncken JW, Kieboom K, Berns A, van Lohuizen M: Bmi-1 collaborates with c-Myc in tumourigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev. 1999, 13: 2678-2690. 10.1101/gad.13.20.2678.CrossRefPubMedPubMedCentral
24.
go back to reference Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M: The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature. 1999, 397: 164-168. 10.1038/16476.CrossRefPubMed Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M: The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature. 1999, 397: 164-168. 10.1038/16476.CrossRefPubMed
25.
go back to reference Sherr CJ: The INK4/ARF network in tumour suppression. Nat Rev. 2001, 2: 731-737. 10.1038/35096061.CrossRef Sherr CJ: The INK4/ARF network in tumour suppression. Nat Rev. 2001, 2: 731-737. 10.1038/35096061.CrossRef
26.
go back to reference Dimri GP, Martinez JL, Jacobs JJ, Keblusek P, Itahana K, Van Lohuizen M, Campisi J, Wazer DE, Band V: The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res. 2002, 62: 4736-4745.PubMed Dimri GP, Martinez JL, Jacobs JJ, Keblusek P, Itahana K, Van Lohuizen M, Campisi J, Wazer DE, Band V: The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res. 2002, 62: 4736-4745.PubMed
27.
go back to reference Silva J, García JM, Peña C, García V, Domínguez G, Suárez D, Camacho FI, Espinosa R, Provencio M, España P, et al: Implication of Polycomb members Bmi-1, Mel-18 and Hpc-2 in the regulation of p16INK4a, p14ARF, h-TERT and c-Myc expression in primary breast carcinomas. Clin Cancer Res. 2006, 12: 6929-6936. 10.1158/1078-0432.CCR-06-0788.CrossRefPubMed Silva J, García JM, Peña C, García V, Domínguez G, Suárez D, Camacho FI, Espinosa R, Provencio M, España P, et al: Implication of Polycomb members Bmi-1, Mel-18 and Hpc-2 in the regulation of p16INK4a, p14ARF, h-TERT and c-Myc expression in primary breast carcinomas. Clin Cancer Res. 2006, 12: 6929-6936. 10.1158/1078-0432.CCR-06-0788.CrossRefPubMed
28.
go back to reference van Kemenade FJ, Raaphorst FM, Blokzijl T, Fieret E, Hamer KM, Satijn DP, Otte AP, Meijer CJ: Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood. 2001, 97: 3896-3901. 10.1182/blood.V97.12.3896.CrossRefPubMed van Kemenade FJ, Raaphorst FM, Blokzijl T, Fieret E, Hamer KM, Satijn DP, Otte AP, Meijer CJ: Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood. 2001, 97: 3896-3901. 10.1182/blood.V97.12.3896.CrossRefPubMed
29.
go back to reference Beà S, Tort F, Pinyol M, Puig X, Hernández L, Hernández S, Fernandez PL, van Lohuizen M, Colomer D, Campo E: BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res. 2001, 61: 2409-2412.PubMed Beà S, Tort F, Pinyol M, Puig X, Hernández L, Hernández S, Fernandez PL, van Lohuizen M, Colomer D, Campo E: BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res. 2001, 61: 2409-2412.PubMed
30.
go back to reference Raaphorst FM, van Kemenade FJ, Blokzijl T, Fieret E, Hamer KM, Satijn DP, Otte AP, Meijer CJ: Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol. 2000, 157: 709-715.CrossRefPubMedPubMedCentral Raaphorst FM, van Kemenade FJ, Blokzijl T, Fieret E, Hamer KM, Satijn DP, Otte AP, Meijer CJ: Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol. 2000, 157: 709-715.CrossRefPubMedPubMedCentral
31.
go back to reference Dukers D, van Galen JC, Giroth C, Jansen P, Sewalt RG, Otte AP, Kluin-Nelemans HC, Meijer CJ, Raaphorst FM: Unique Polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. Am J Pathol. 2004, 164: 873-881.CrossRefPubMedPubMedCentral Dukers D, van Galen JC, Giroth C, Jansen P, Sewalt RG, Otte AP, Kluin-Nelemans HC, Meijer CJ, Raaphorst FM: Unique Polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. Am J Pathol. 2004, 164: 873-881.CrossRefPubMedPubMedCentral
32.
go back to reference Sánchez-Beato M, Sánchez E, García JF, Pérez-Rosado A, Montoya MC, Fraga M, Artiga MJ, Navarrete M, Abraira V, Morente M, et al: Abnormal PcG protein expression in Hodgkin's lymphoma. Relation with E2F6 and NfkappaB transcription factors. J Pathol. 2004, 204: 528-537. 10.1002/path.1661.CrossRefPubMed Sánchez-Beato M, Sánchez E, García JF, Pérez-Rosado A, Montoya MC, Fraga M, Artiga MJ, Navarrete M, Abraira V, Morente M, et al: Abnormal PcG protein expression in Hodgkin's lymphoma. Relation with E2F6 and NfkappaB transcription factors. J Pathol. 2004, 204: 528-537. 10.1002/path.1661.CrossRefPubMed
33.
go back to reference van Galen JC, Muris JJ, Oudejans JJ, Vos W, Giroth CP, Ossenkoppele GJ, Otte AP, Raaphorst FM, Meijer CJ: Expression of the polycomb-group gene BMI-1 is related to an unfavourable prognosis in primary nodal DLBCL. J Clin Pathol. 2007, 60: 167-172. 10.1136/jcp.2006.038752.CrossRefPubMed van Galen JC, Muris JJ, Oudejans JJ, Vos W, Giroth CP, Ossenkoppele GJ, Otte AP, Raaphorst FM, Meijer CJ: Expression of the polycomb-group gene BMI-1 is related to an unfavourable prognosis in primary nodal DLBCL. J Clin Pathol. 2007, 60: 167-172. 10.1136/jcp.2006.038752.CrossRefPubMed
34.
go back to reference Vonlanthen S, Heighway J, Altermatt HJ, Gugger M, Kappeler A, Borner MM, van Lohuizen M, Betticher DC: The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer. 2001, 84: 1372-1376. 10.1054/bjoc.2001.1791.CrossRefPubMedPubMedCentral Vonlanthen S, Heighway J, Altermatt HJ, Gugger M, Kappeler A, Borner MM, van Lohuizen M, Betticher DC: The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer. 2001, 84: 1372-1376. 10.1054/bjoc.2001.1791.CrossRefPubMedPubMedCentral
35.
go back to reference Leung C, Lingbeek M, Shakhova O, Liu J, Tanger E, Saremaslani P, Van Lohuizen M, Marino S: Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature. 2004, 428: 337-341. 10.1038/nature02385.CrossRefPubMed Leung C, Lingbeek M, Shakhova O, Liu J, Tanger E, Saremaslani P, Van Lohuizen M, Marino S: Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature. 2004, 428: 337-341. 10.1038/nature02385.CrossRefPubMed
36.
go back to reference Nowak K, Kerl K, Fehr D, Kramps C, Gessner C, Killmer K, Samans B, Berwanger B, Christiansen H, Lutz W: BMI-1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas. Nucleic Acids Res. 2006, 34: 1745-1754. 10.1093/nar/gkl119.CrossRefPubMedPubMedCentral Nowak K, Kerl K, Fehr D, Kramps C, Gessner C, Killmer K, Samans B, Berwanger B, Christiansen H, Lutz W: BMI-1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomas. Nucleic Acids Res. 2006, 34: 1745-1754. 10.1093/nar/gkl119.CrossRefPubMedPubMedCentral
37.
go back to reference Neo SY, Leow CK, Vega VB, Long PM, Islam AF, Lai PB, Liu ET, Ren EC: Identification of discriminators of hepatoma by gene expression profiling using a minimal dataset approach. Hepathology. 2004, 39: 944-953. 10.1002/hep.20105.CrossRef Neo SY, Leow CK, Vega VB, Long PM, Islam AF, Lai PB, Liu ET, Ren EC: Identification of discriminators of hepatoma by gene expression profiling using a minimal dataset approach. Hepathology. 2004, 39: 944-953. 10.1002/hep.20105.CrossRef
38.
go back to reference Kim JH, Yoon SY, Jeong SH, Kim SY, Moon SK, Joo JH, Lee Y, Choe IS, Kim JW: Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast. 2004, 13: 383-388. 10.1016/j.breast.2004.02.010.CrossRefPubMed Kim JH, Yoon SY, Jeong SH, Kim SY, Moon SK, Joo JH, Lee Y, Choe IS, Kim JW: Overexpression of Bmi-1 oncoprotein correlates with axillary lymph node metastases in invasive ductal breast cancer. Breast. 2004, 13: 383-388. 10.1016/j.breast.2004.02.010.CrossRefPubMed
39.
go back to reference Kim JH, Yoon SY, Kim CN, Joo JH, Moon SK, Choe IS, Choe YK, Kim JW: The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett. 2004, 203: 217-224. 10.1016/j.canlet.2003.07.009.CrossRefPubMed Kim JH, Yoon SY, Kim CN, Joo JH, Moon SK, Choe IS, Choe YK, Kim JW: The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins. Cancer Lett. 2004, 203: 217-224. 10.1016/j.canlet.2003.07.009.CrossRefPubMed
40.
go back to reference Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL, Shao JY, Wu QL, Li MZ, Xia YF, et al: Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res. 2006, 66: 6225-6232. 10.1158/0008-5472.CAN-06-0094.CrossRefPubMed Song LB, Zeng MS, Liao WT, Zhang L, Mo HY, Liu WL, Shao JY, Wu QL, Li MZ, Xia YF, et al: Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells. Cancer Res. 2006, 66: 6225-6232. 10.1158/0008-5472.CAN-06-0094.CrossRefPubMed
41.
go back to reference Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV: Essential role for activation of the Polycomb group [PcG] protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle. 2006, 5: 1886-1901.CrossRefPubMed Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV: Essential role for activation of the Polycomb group [PcG] protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle. 2006, 5: 1886-1901.CrossRefPubMed
42.
go back to reference Sjögren S, Inganäs M, Torbjörn N: The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst. 1996, 88: 173-182. 10.1093/jnci/88.3-4.173.CrossRefPubMed Sjögren S, Inganäs M, Torbjörn N: The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst. 1996, 88: 173-182. 10.1093/jnci/88.3-4.173.CrossRefPubMed
43.
go back to reference Mihara K, Chowdhury M, Nakaju N, Hidani S, Ihara A, Hyodo H, Yasunaga S, Takihara Y, Kimura A: Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and prognosis of the patients. Blood. 2006, 107: 305-308. 10.1182/blood-2005-06-2393.CrossRefPubMed Mihara K, Chowdhury M, Nakaju N, Hidani S, Ihara A, Hyodo H, Yasunaga S, Takihara Y, Kimura A: Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and prognosis of the patients. Blood. 2006, 107: 305-308. 10.1182/blood-2005-06-2393.CrossRefPubMed
Metadata
Title
Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patients
Authors
Javier Silva
Vanesa García
José M García
Cristina Peña
Gemma Domínguez
Raquel Díaz
Yolanda Lorenzo
Alicia Hurtado
Antonio Sánchez
Félix Bonilla
Publication date
01-08-2007
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 4/2007
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1760

Other articles of this Issue 4/2007

Breast Cancer Research 4/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine